Daniel Asher Purchases 15,540 Shares of Ekso Bionics (NASDAQ:EKSO) Stock

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) major shareholder Daniel Asher bought 15,540 shares of Ekso Bionics stock in a transaction that occurred on Thursday, February 19th. The shares were acquired at an average price of $12.30 per share, for a total transaction of $191,142.00. Following the completion of the transaction, the insider directly owned 270,432 shares of the company’s stock, valued at $3,326,313.60. This trade represents a 6.10% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ekso Bionics Trading Down 9.1%

EKSO traded down $1.12 during midday trading on Friday, hitting $11.18. The company’s stock had a trading volume of 131,128 shares, compared to its average volume of 291,404. Ekso Bionics Holdings, Inc. has a 52-week low of $2.73 and a 52-week high of $13.27. The firm has a 50-day moving average price of $8.17 and a two-hundred day moving average price of $5.69. The company has a current ratio of 1.66, a quick ratio of 1.09 and a debt-to-equity ratio of 0.11. The firm has a market cap of $29.29 million, a P/E ratio of -1.97 and a beta of 0.80.

Analyst Upgrades and Downgrades

EKSO has been the topic of a number of recent analyst reports. HC Wainwright downgraded shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. Wall Street Zen upgraded Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.50.

Institutional Investors Weigh In On Ekso Bionics

Large investors have recently modified their holdings of the stock. Consolidated Portfolio Review Corp acquired a new position in shares of Ekso Bionics in the 3rd quarter valued at approximately $333,000. Shay Capital LLC acquired a new stake in shares of Ekso Bionics during the third quarter worth approximately $67,000. Virtu Financial LLC bought a new stake in shares of Ekso Bionics in the third quarter worth $57,000. Citadel Advisors LLC acquired a new stake in Ekso Bionics in the third quarter valued at $198,000. Finally, Geode Capital Management LLC boosted its stake in Ekso Bionics by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after acquiring an additional 10,281 shares during the last quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.